文献速递白血病MDS 与骨髓增殖性肿瘤

SMAC模拟物作为髓系恶性肿瘤的潜在治疗药物

SMAC mimetics as potential cancer therapeutics in myeloid malignancies.
PubMed 文献 · Br J Haematol · 2019-03-05

本文综述了SMAC模拟物靶向IAP蛋白治疗髓系恶性肿瘤的研发与治疗原理。临床前研究显示SMAC模拟物与多种治疗药物(细胞毒化疗、受体酪氨酸激酶抑制剂、死亡受体靶向药物、坏死性凋亡或自噬诱导剂及免疫检查点阻断)具有广泛协同活性,通过增敏化疗对恶性细胞的作用展现治疗前景。SMAC模拟物作为单药或精心选择的联合方案,为高危、化疗难治性血液肿瘤患者的进一步研究提供了新途径。

要点

  • IAP蛋白参与多种髓系恶性肿瘤,中和IAP可降低癌细胞凋亡阈值。
  • SMAC模拟物在临床前研究中与多种治疗药物显示广泛协同活性。
  • SMAC模拟物可作为单药或联合方案用于高危、化疗难治性血液肿瘤的进一步研究。

核心结论

  • SMAC模拟物在临床前研究中通过增敏化疗对恶性细胞的作用显示出治疗前景。
  • SMAC模拟物代表了一种在高危、化疗难治性血液肿瘤患者中进一步研究的新方法,可作为单药或精心选择的联合方案。

研究设计与样本

  • 本文为综述,讨论小分子SMAC模拟物的开发与治疗原理,重点介绍处于临床开发阶段的髓系恶性肿瘤治疗药物。

主要发现

  • IAP拮抗方式可能包括下调IAP表达、上调内源性促凋亡蛋白(如肿瘤坏死因子-α或Fas配体)或直接拮抗IAP对caspases的活性。
  • 在临床前研究中,SMAC模拟物与多种治疗药物(包括细胞毒化疗、受体酪氨酸激酶抑制剂、死亡受体靶向药物、坏死性凋亡或自噬等替代细胞死亡机制及免疫检查点阻断)表现出广泛协同活性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Evasion of apoptosis has been identified as one of the essential hallmarks of cancer. Inhibitor of apoptosis proteins (IAPs) are implicated in a host of myeloid malignancies, providing the rationale for strategies aimed at neutralizing IAPs to lower the cancer cell apoptosis threshold. Modes of IAP antagonism may include down-regulating IAP expression, up-regulating endogenous pro-apoptotic proteins, such as tumour necrosis factor-α or Fas ligand, or directly antagonizing IAP activity against caspases. Direct targeting of IAPs using mimetics of the second mitochondria-derived activator of caspase (SMAC) protein has shown therapeutic promise by sensitizing the effect of chemotherapy on malignant cells. In pre-clinical studies, SMAC mimetics have demonstrated broad synergistic activity with a wide range of therapeutics, including cytotoxic chemotherapy, receptor tyrosine kinase inhibitors, agents targeting death receptors and alternative mechanisms of cell death, such as necroptosis or autophagy and immune check point blockade. SMAC mimetics represent a novel approach for further investigation in patients with high-risk, chemo-refractory blood cancers, as single agents or in thoughtfully selected combinations. In this review, we discuss the development and therapeutic rationale of small molecule SMAC mimetics, with an emphasis on agents in clinical development for myeloid malignancies.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Boddu P, Carter BZ, Verstovsek S, et al. SMAC mimetics as potential cancer therapeutics in myeloid malignancies. Br J Haematol. 2019. PMID: 30836448. doi:10.1111/bjh.15829

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。